Get the Stockscreener App
43.93
4.03%
1.70
Pre-market:
44.10
0.17
+0.39%
Moderna Inc stock is traded at $43.93, with a volume of 10.42M.
It is up +4.03% in the last 24 hours and up +5.02% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$42.23
Open:
$42.28
24h Volume:
10.42M
Relative Volume:
0.90
Market Cap:
$17.16B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-5.0321
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+4.61%
1M Performance:
+5.02%
6M Performance:
+56.78%
1Y Performance:
+33.16%
1-Day Range:
$41.97
$45.07
1-Week Range:
$36.66
$45.07
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
43.93 | 16.50B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.32 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.53 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.55 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.61 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.86 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Flu Vaccine Debate Could Resolve With Postmarket Study, FDA’s Makary Suggests - Citeline News & Insights
Judge Trims Moderna's Defenses In COVID Patent Suit - Law360
Moderna Loses Key Covid-Shot Patent Defenses Before Jury Trial - Bloomberg Law News
This Week's Healthcare Earnings: Moderna, Tenet And More - Law360
Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial - TradingView
Key facts: Moderna's COVID-19 vaccine gains EU approval; price targets rise - TradingView
The Analyst Verdict: Moderna In The Eyes Of 9 Experts - Benzinga
Moderna (NASDAQ:MRNA) Given New $41.00 Price Target at The Goldman Sachs Group - MarketBeat
Goldman Sachs Maintains Neutral Rating but Raises Price Target o - GuruFocus
MRNA: RBC Capital Maintains Rating and Raises Price Target | MRN - GuruFocus
Moderna (MRNA) Sees Bullish Activity with Increased Call Options - GuruFocus
Moderna's COVID-19 Vaccine mNEXSPIKE Receives EU Marketing Authorization - Intellectia AI
Moderna Stock Rises After EU Marketing Authorization For mNEXSPIKE - Benzinga
Moderna (MRNA) Price Target Raised to $35 by Evercore ISI Group - GuruFocus
Bernstein Adjusts Price Target on Moderna to $45 From $35, Maintains Market Perform Rating - marketscreener.com
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline - FinancialContent
RBC raises Moderna stock price target to $30 on pipeline progress - Investing.com UK
RBC Capital Adjusts Price Target on Moderna to $30 From $25, Maintains Sector Perform Rating - marketscreener.com
Moderna Gets Approval for COVID Vaccine From European Commission - marketscreener.com
Moderna receives European Commission marketing authorization for Covid-19 vaccine Mnexspike - marketscreener.com
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE - The Derrick
New Moderna COVID shot shows 9.3% edge in trial, now cleared in Europe - Stock Titan
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90 - simplywall.st
Analyst recommendations: Accenture, Dollar Tree, DraftKings, Moderna, Walmart… - marketscreener.com
Editorial: Letting disease win — FDA’s dangerous refusal of Moderna’s new mRNA flu vaccine - The Daily Gazette
Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push - BioSpace
To save seniors’ lives, Trump must stomp on this deadly anti-vax call - New York Post
Moderna Q4 2025 net loss narrows; revenue drops 30% - AlphaStreet News
US FDA Refuse-To-File Letters Hit The Big Time With Moderna’s Flu Vaccine - Citeline News & Insights
Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait - BioSpace
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - TradingView
Tobam Lowers Holdings in Moderna, Inc. $MRNA - MarketBeat
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
Is Moderna (MRNA) Pricing Reflecting Potential After Sharp Multi‑Year Share Price Pullback? - Yahoo Finance
This Is What Destroying the Vaccine Market Looks Like - The Bulwark
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Lisa Jarvis: Moderna’s flu shot ordeal hurts innovation — and public health - The Daily Gazette
Can Moderna Inc. weather a recessionEarnings Recap Report & Technical Buy Zone Confirmations - mfd.ru
Moderna (MRNA) Tops Q4 Estimates Despite Regulatory Setback - GuruFocus
U.S. vaccine policy under RFK Jr. challenged in court (PFE) - Seeking Alpha
Earnings Scorecard: Healthcare sector shows strong top-line pulse - Seeking Alpha
Moderna looks outside US for growth after FDA’s flu shot refusal - WTVB
MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook - Finviz
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - TheDailyJournal.com
CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot - The Cancer Letter
Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results - FinancialContent
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend - FXEmpire
Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron's
Moderna Has A Few Words For The FDA After mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):